|
2022-06-07 |
2022-06-06 |
S
Venta
|
Chief Executive Officer
Consejero ejecutivo
|
60 795
-26.6%
432,88
3.915.891 US$
|
60 795
-26.6%
|
432,88
|
3.915.891 US$
|
|
|
2022-06-07 |
2022-06-06 |
S
Venta
|
Chief Financial Officer
Oficial
|
57 363
+6.4%
365,37
4.755.801 US$
|
57 363
+6.4%
|
365,37
|
4.755.801 US$
|
|
|
2022-04-01 |
2022-03-31 |
S
Venta
|
VP, Clinical Dev & Med Affairs
Oficial
|
70 388
+35.2%
397,09
379.738 US$
|
70 388
+35.2%
|
397,09
|
379.738 US$
|
|
|
2022-04-01 |
2022-03-31 |
S
Venta
|
Chief Financial Officer
Oficial
|
8 116
-5.3%
0,21
1.705 US$
|
8 116
-5.3%
|
0,21
|
1.705 US$
|
|
|
2022-04-01 |
2022-03-31 |
S
Venta
|
Chief Executive Officer
Consejero ejecutivo
|
23 633
-4.9%
0,21
4.965 US$
|
23 633
-4.9%
|
0,21
|
4.965 US$
|
|
|
2021-11-24 |
2021-11-23 |
S
Venta
|
Consejero no ejecutivo
|
10 000
-18.7%
0,60
6.018 US$
|
10 000
-18.7%
|
0,60
|
6.018 US$
|
|
|
2021-06-07 |
2021-06-04 |
S
Venta
|
See Remarks
Oficial
|
1 709
-3.3%
0,81
1.376 US$
|
1 709
-3.3%
|
0,81
|
1.376 US$
|
|
|
2021-06-07 |
2021-06-04 |
S
Venta
|
VP, Clinical Dev & Med Affairs
Oficial
|
1 709
-3.3%
0,81
1.376 US$
|
1 709
-3.3%
|
0,81
|
1.376 US$
|
|
|
2021-06-07 |
2021-06-04 |
S
Venta
|
Chief Financial Officer
Oficial
|
1 709
-1.7%
0,81
1.376 US$
|
1 709
-1.7%
|
0,81
|
1.376 US$
|
|
|
2019-04-18 |
2019-04-11 |
B
Compra
|
President & CEO
Consejero ejecutivo
|
100 000
+55.5%
3,50
350.000 US$
|
100 000
+55.5%
|
3,50
|
350.000 US$
|
|
|
2018-02-28 |
2018-02-27 |
S
Venta
|
Amzak Capital Management, LLC
Gran accionista
|
5 901
-100.0%
8,26
48.760 US$
|
5 901
-100.0%
|
8,26
|
48.760 US$
|
|
|
2018-02-28 |
2018-02-27 |
S
Venta
|
Amzak Capital Management, LLC
Gran accionista
|
80 880
-31.6%
8,36
675.914 US$
|
80 880
-31.6%
|
8,36
|
675.914 US$
|
|
|
2018-02-28 |
2018-02-26 |
S
Venta
|
Amzak Capital Management, LLC
Gran accionista
|
1 500
-0.6%
11,00
16.500 US$
|
1 500
-0.6%
|
11,00
|
16.500 US$
|
|
|
2017-12-08 |
2017-12-06 |
B
Compra
|
GREATHOUSE KENNETH
|
55 000
+37.9%
0,61
33.407 US$
|
55 000
+37.9%
|
0,61
|
33.407 US$
|
|
|
2017-12-04 |
2017-12-01 |
B
Compra
|
GREATHOUSE KENNETH
|
50 000
+52.6%
0,62
31.080 US$
|
50 000
+52.6%
|
0,62
|
31.080 US$
|
|
|
2017-12-04 |
2017-11-30 |
B
Compra
|
GREATHOUSE KENNETH
|
45 000
+90.0%
0,62
27.927 US$
|
45 000
+90.0%
|
0,62
|
27.927 US$
|
|
|
2017-11-16 |
2017-11-15 |
B
Compra
|
GREATHOUSE KENNETH
|
15 000
+42.9%
0,58
8.674 US$
|
15 000
+42.9%
|
0,58
|
8.674 US$
|
|
|
2017-11-16 |
2017-11-14 |
B
Compra
|
GREATHOUSE KENNETH
|
35 000
+inf%
0,64
22.484 US$
|
35 000
+inf%
|
0,64
|
22.484 US$
|
|
|
2017-05-25 |
2017-05-25 |
B
Compra
|
Erbez Georgia
CFO and Chief Business Officer
Oficial
|
68 000
+142.4%
1,32
89.760 US$
|
68 000
+142.4%
|
1,32
|
89.760 US$
|
|
|
2017-05-25 |
2017-05-25 |
B
Compra
|
WALKER JOHN PETER
Interim CEO
Consejero ejecutivo
|
37 550
+22.2%
1,37
51.338 US$
|
37 550
+22.2%
|
1,37
|
51.338 US$
|
|
|
2017-05-25 |
2017-05-24 |
B
Compra
|
WALKER JOHN PETER
Interim CEO
Consejero ejecutivo
|
36 166
+27.2%
1,34
48.553 US$
|
36 166
+27.2%
|
1,34
|
48.553 US$
|
|
|
2017-02-14 |
2017-02-13 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
1 099 996
-53.6%
2,01
2.211.432 US$
|
1 099 996
-53.6%
|
2,01
|
2.211.432 US$
|
|
|
2017-02-14 |
2017-02-13 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
1 099 996
-53.6%
2,01
2.211.432 US$
|
1 099 996
-53.6%
|
2,01
|
2.211.432 US$
|
|
|
2016-09-20 |
2016-09-16 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
7 471
-0.4%
0,75
5.603 US$
|
7 471
-0.4%
|
0,75
|
5.603 US$
|
|
|
2016-09-20 |
2016-09-16 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
7 471
-0.4%
0,75
5.603 US$
|
7 471
-0.4%
|
0,75
|
5.603 US$
|
|
|
2016-09-15 |
2016-09-13 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
10 000
-0.5%
0,74
7.400 US$
|
10 000
-0.5%
|
0,74
|
7.400 US$
|
|
|
2016-09-15 |
2016-09-13 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
10 000
-0.5%
0,74
7.400 US$
|
10 000
-0.5%
|
0,74
|
7.400 US$
|
|
|
2016-08-31 |
2016-08-29 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
50 000
-2.4%
1,01
50.440 US$
|
50 000
-2.4%
|
1,01
|
50.440 US$
|
|
|
2016-08-31 |
2016-08-29 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
50 000
-2.4%
1,01
50.440 US$
|
50 000
-2.4%
|
1,01
|
50.440 US$
|
|
|
2016-08-26 |
2016-08-24 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
1 200
-0.1%
1,21
1.452 US$
|
1 200
-0.1%
|
1,21
|
1.452 US$
|
|
|
2016-08-26 |
2016-08-24 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
1 200
-0.1%
1,21
1.452 US$
|
1 200
-0.1%
|
1,21
|
1.452 US$
|
|
|
2016-08-22 |
2016-08-19 |
B
Compra
|
Erbez Georgia
Interim CFO
Oficial
|
47 750
+inf%
1,32
63.030 US$
|
47 750
+inf%
|
1,32
|
63.030 US$
|
|
|
2016-08-22 |
2016-08-19 |
B
Compra
|
KELLERMAN DONALD J
VP, Clinical Dev & Med Affairs
Oficial
|
15 920
+inf%
1,32
21.014 US$
|
15 920
+inf%
|
1,32
|
21.014 US$
|
|
|
2016-08-22 |
2016-08-19 |
B
Compra
|
Lewis Hayley
VP, Reg Affairs & Quality
Oficial
|
4 775
+inf%
1,32
6.303 US$
|
4 775
+inf%
|
1,32
|
6.303 US$
|
|
|
2016-08-22 |
2016-08-19 |
B
Compra
|
WALKER JOHN PETER
Consejero no ejecutivo
|
63 700
+inf%
1,32
84.084 US$
|
63 700
+inf%
|
1,32
|
84.084 US$
|
|
|
2016-08-22 |
2016-08-19 |
B
Compra
|
Alataris Konstantinos
President, CEO
Consejero ejecutivo
|
127 389
+inf%
1,32
168.153 US$
|
127 389
+inf%
|
1,32
|
168.153 US$
|
|
|
2016-08-22 |
2016-08-19 |
B
Compra
|
XANTHOPOULOS KLEANTHIS G
Consejero no ejecutivo
|
15 920
+265.3%
1,32
21.014 US$
|
15 920
+265.3%
|
1,32
|
21.014 US$
|
|
|
2016-07-21 |
2016-07-21 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
8 989
-0.4%
1,33
11.957 US$
|
8 989
-0.4%
|
1,33
|
11.957 US$
|
|
|
2016-07-21 |
2016-07-21 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
8 989
-0.4%
1,33
11.957 US$
|
8 989
-0.4%
|
1,33
|
11.957 US$
|
|
|
2016-07-21 |
2016-07-20 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
14 158
-0.7%
1,24
17.550 US$
|
14 158
-0.7%
|
1,24
|
17.550 US$
|
|
|
2016-07-21 |
2016-07-20 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
14 158
-0.7%
1,24
17.550 US$
|
14 158
-0.7%
|
1,24
|
17.550 US$
|
|
|
2016-07-21 |
2016-07-19 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
534
-0.0%
1,17
625 US$
|
534
-0.0%
|
1,17
|
625 US$
|
|
|
2016-07-21 |
2016-07-19 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
534
-0.0%
1,17
625 US$
|
534
-0.0%
|
1,17
|
625 US$
|
|
|
2016-07-15 |
2016-07-13 |
S
Venta
|
BARRETT M JAMES
Gran accionista
|
13 382
-0.6%
1,20
16.060 US$
|
13 382
-0.6%
|
1,20
|
16.060 US$
|
|
|
2016-07-15 |
2016-07-13 |
S
Venta
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
13 382
-0.6%
1,20
16.060 US$
|
13 382
-0.6%
|
1,20
|
16.060 US$
|
|
|
2015-02-02 |
2015-01-30 |
B
Compra
|
BARRETT M JAMES
Consejero no ejecutivo
Gran accionista
|
23 457
+1.1%
11,00
258.027 US$
|
23 457
+1.1%
|
11,00
|
258.027 US$
|
|
|
2015-02-02 |
2015-01-30 |
B
Compra
|
New Enterprise Associates 12, Limited Partnership
Gran accionista
|
23 457
+1.1%
11,00
258.027 US$
|
23 457
+1.1%
|
11,00
|
258.027 US$
|
|
|
2015-02-02 |
2015-01-30 |
B
Compra
|
BioMed Realty Trust Inc
Gran accionista
|
26 543
+5.1%
11,00
291.973 US$
|
26 543
+5.1%
|
11,00
|
291.973 US$
|
|